tbuckley/cabot-search huggingface dataset:
Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes
Authors: Ify R. Mordi, Ivy Li, Gittu George, Rory J. McCrimmon, Colin N. Palmer, Ewan R. Pearson, Chim C. Lang, Alex S. Doney
Journal: Diabetes Care (2024)

OBJECTIVE The recent availability of cardiovascular risk-reducing type 2 diabetes (T2D) therapies makes it imperative to optimally identify individuals who could derive benefit. Current clinical risk prediction may misclassify individuals as low risk and could be improved. Our aim was to determine the incremental prognostic value of a coronary heart disease (CHD) genome-wide polygenic risk score (PRS) to a clinical risk score in prediction of major adverse cardiovascular events (MACE) in patients with T2D. RESEARCH DESIGN AND METHODS We evaluated 10,556 individuals with T2D aged 40–79 years without a prior cardiovascular hospitalization. We calculated 10-year clinical cardiovascular risk at the date of recruitment using the Pooled Cohort Equation (PCE Risk) and constructed a CHD PRS. The primary outcome was time to first MACE incidence, and we assessed the additional incremental predictive value of the CHD PRS to the PCE risk. RESULTS At 10 years, there were 1,477 MACE. After adjustment for clinical risk, the CHD PRS was significantly associated with MACE (hazard ratio [HR] 1.69 per SD increase, 95% CI 1.60–1.79). Individuals with PCE Risk &amp;lt;7.5% but in the top quintile of CHD PRS had a significantly increased likelihood of MACE (HR 10.69, 95% CI 5.07–22.55) compared with those in the lowest. The addition of the PRS to the clinical risk score led to significant improvements in risk prediction, particularly in those at low clinical risk. CONCLUSIONS The addition of a CHD PRS to clinical assessment improved MACE prediction in T2D individuals without prior cardiovascular disease, particularly in those at low clinical risk.
EP.17D.01 Trends in Lung Cancer Incidence Among Individuals Under 50: A Retrospective Analysis of the National Inpatient Sample (NIS) Database
Authors: N.A. Guevara Rodriguez, E. Perez, V. Chapiolkina, P. Budhathoki, G.W. Stoel, N. Florez, C. Olazagasti
Journal: Journal of Thoracic Oncology (2024)
EP.07B.07 The Impact of Radiation Therapy on Lung Cancer Patients with Interstitial Lung Disease
Authors: S. Genet, E. Yogiaveetil, N. Shaverdian, A. Wu, C.B. Simone, J. Shin, D.Y. Gelblum, P. Iyengar, A. Rimner, D.R. Gomez, A.F. Shepherd
Journal: Journal of Thoracic Oncology (2024)
EP.15A.01 Lung Cancer Patients in a Nationwide Oncology Navigation Program
Authors: C. Baldotto, A. Colli, F. de Oliveira Marques, R. de Andrade Trajano, T.P. Moraes Coelho, A.C. Machado, M.V.J. dos Santos, E. Mascarenhas
Journal: Journal of Thoracic Oncology (2024)
EP.07G.08 Predicting Lung Cancer Recurrence in the Pre-Operative Setting Using AI/radiomics: A Study Based on US and European Cohorts
Authors: A. Valter, T. Kordemets, A. Cambray, A. Gasimova, N. Waterfield Price, L. Freitag, A. Vachani, D. Carbone, K. Oselin
Journal: Journal of Thoracic Oncology (2024)
EP.11B.05 The Differential Effect of Radiation, IL39, and the Combination on Expression of HLA Molecules
Authors: K. D'mello, E. Kaser, C. Hu, M. Lequio, Z. Zhu, Z. Hunzeker, A. Heslin, H. Xiao, Q. Bai, M. Wakefield, Y. Fang
Journal: Journal of Thoracic Oncology (2024)
EP.07B.05 Comparison of Image-Guided Thermal Ablation or Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer
Authors: J. Nikitas, C. Kashani, T. Oughourlian, N. Jahanshahi, M. Yokomizo, S. Tappuni, S. Nesbit, A. Lee, J. Deng, M. Steinberg, S. Genshaft, R. Suh, F. Abtin, D. Moghanaki
Journal: Journal of Thoracic Oncology (2024)
EP.08A.02 Adherence to Adjuvant Immunotherapy and Target Therapy Protocols Inpatients with Resected NSCLC: A Meta Analysis
Authors: P. Bertoglio, F. Gallina, D. Marinelli, A. Nuccio, A. Di Federico, F. Ambrosi, E. Faccioli, R. Ferrara, E. Balzani, A. Ferro, R. Giusti, M. Mammana, A. Pittaro, M. Sepulcri, G. Viscardi, F. Guerrera
Journal: Journal of Thoracic Oncology (2024)
EP.12H.07 A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC
Authors: J. Malhotra, X. Li, J. Palmer, T.W. Synold, A. Mohanty, S. Singhal, P. Kulkarni, R. Salgia
Journal: Journal of Thoracic Oncology (2024)
EP.09A.06 Assessment of Treatment Outcomes and Chest Wall Toxicity Following Stereotactic Body Radiotherapy for Lung Nodules Adjacent to the Pleura
Authors: S. Oz, O. Bascik, S. Duru Birgi, Y. Arslan, A. Kayi Cangir, S. Akyurek
Journal: Journal of Thoracic Oncology (2024)
EP.11A.27 Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab.
Authors: M. Tuller, G. Buela, Y. Ferreira, A. Antivero, L. Lupinacci, L. Basbus
Journal: Journal of Thoracic Oncology (2024)
EP.13C.01 Prognosis of Surgically Resected Pure and Combined Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy
Authors: N. Tsurumaki, Y. Goto, Y. Shinno, Y. Okuma, T. Yoshida, H. Horinouchi, N. Yamamoto, Y. Matsumoto, S. Watanabe, Y. Yatabe, Y. Ohe
Journal: Journal of Thoracic Oncology (2024)
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Authors: E.-B. Braune, I.J. Zwicky Eide, O. Grundberg, L. De Petris, O.T. Brustugun, S. Ekman, P. Hydbring
Journal: Journal of Thoracic Oncology (2024)
EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series
Authors: E. Bertoli, E. De Carlo, M. Montico, A. Del Conte, B. Stanzione, A. Bearz
Journal: Journal of Thoracic Oncology (2024)
EP.07B.01 Definitions of Local Control after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer Reported in the Literature
Authors: N. Nourmohammadi, C. Kashani, J. Nikitas, T. Oughourlian, J. Bradley, M. Guckenberger, S. Siva, D. Palma, S.S. Yom, S. Senan, D. Moghanaki
Journal: Journal of Thoracic Oncology (2024)
EP.07A.22 The Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma
Authors: T. Takenaka, K. Ozono, M. Kohno, T. Akamine, F. Kinoshita, Y. Nakanishi, T. Yoshizumi
Journal: Journal of Thoracic Oncology (2024)
EP.05A.03 The Accuracy of EBUS, EUS, EBUS Plus EUS, and Mediastinoscopy for Mediastinal Staging in NSCLC - A Systematic Review and Meta-Analysis
Authors: C. Baldotto, E. Mascarenhas, A. Gelatti, T. Vilas Boas Reis, M. Corassa, C.H. Andrade Teixeira, G. Castro, V.C. Cordeiro de Lima
Journal: Journal of Thoracic Oncology (2024)
EP.06G.13 TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients
Authors: J.P.C. Apolinário, C.C. Avelar, L.L.d.S. Campos, E.M. de Lima, P.H.C. Diniz
Journal: Journal of Thoracic Oncology (2024)
Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications
Authors: Umesh Chandra Dash, Nitish Kumar Bhol, Sandeep Kumar Swain, Rashmi Rekha Samal, Prabhat Kumar Nayak, Vishakha Raina, Sandeep Kumar Panda, Rout George Kerry, Asim K Duttaroy, Atala Bihari Jena
Journal: Acta Pharmaceutica Sinica B (2024)

Neuroprotection is a proactive approach to safeguarding the nervous system, including the brain, spinal cord, and peripheral nerves, by preventing or limiting damage to nerve cells and other components. It primarily defends the central nervous system against injury from acute and progressive neurodegenerative disorders. Oxidative stress, an imbalance between the body's natural defense mechanisms and the generation of reactive oxygen species, is crucial in developing neurological disorders. Due to its high metabolic rate and oxygen consumption, the brain is particularly vulnerable to oxidative stress. Excessive ROS damages the essential biomolecules, leading to cellular malfunction and neurodegeneration. Several neurological disorders, including Alzheimer's, Parkinson's, Amyotrophic lateral sclerosis, multiple sclerosis, and ischemic stroke, are associated with oxidative stress. Understanding the impact of oxidative stress in these conditions is crucial for developing new treatment methods. Researchers are exploring using antioxidants and other molecules to mitigate oxidative stress, aiming to prevent or slow down the progression of brain diseases. By understanding the intricate interplay between oxidative stress and neurological disorders, scientists hope to pave the way for innovative therapeutic and preventive approaches, ultimately improving individuals' living standards.
EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN
Authors: S. Khan, K. Hueniken, C.M. Brown, K. Tan, A.S. Wenzlaff, G. Fernandez-Tardon, A. Pesatori, M.J. Barnett, J. Kothari, H. Ma, M. Pérez-Ríos, M.P.A. Davies, B. Schöttker, J. Xie, N.B. Leighl, M. Tsao, J. Zhang, H. Brenner, A.S. Andrew, Y. Wang, J.K. Field, A. Ruano-Ravina, M.B. Schabath, H. Shen, L. Le Marchand, D.C. Christiani, M.L. Neuhouser, M.T. Landi, A. Tardon, F. Taylor, A.G. Schwartz, P. Yang, R.J. Hung, W. Xu, F.A. Shepherd, G. Liu
Journal: Journal of Thoracic Oncology (2024)
EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.
Authors: M.G. Savadkoohi, A.G. Gouveia, D.A. Ribeiro, G. Anagnostopoulos, T. Chow, O. Ostapiak, V. Yordanov, G. Hajdok, A. Swaminath, G. Okawara, J. Wright, G.R. Pond, T.G. Tsakiridis
Journal: Journal of Thoracic Oncology (2024)
EP.07E.04 Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs
Authors: J. Ye, J. Liu, Y. Yang, W. Lv, W. Xu, P. Xia, L. Wang, L. Zhu, J. Hu
Journal: Journal of Thoracic Oncology (2024)
EP.07A.24 European Experience of Early-Stage NSCLC Patients with Any Prior Cancer History Following Lobectomy or Segmentectomy
Authors: L.J. Lula, R. Costa, L. Huang, A. Rushwan, M. Domjan, A.J.P.M. Franssen, R. Weedle, B.T. Marinucci, C.F. Barreda, E.G. O¨zgu¨r, C. Jasovic, J. Whooley, R. Ryan, V. Young, P. Fernandes, E.A. Rendina, N.G. Bekiroğlu, E.R. De Loos, M. Jimenez, C. Savu, A. D’andrilli, G.J. Fitzmaurice, T. Stupnik, C.T. Saon, A. Brunelli, R.H. Petersen
Journal: Journal of Thoracic Oncology (2024)
EP.13D.09 Characteristics and Survival in Never-Smoking Small Cell Lung Cancer Cases an Analysis from the Thoracic Tumor Registry
Authors: C. Candal-Pedreira, A. Ruano-Ravina, V. Calvo de Juan, M. Cobo, J.M. Trigo, D. Rodríguez-Abreu, A. Estival, E. Carcereny, M. Cucurull, R. López Castro, A. Medina, R. García Campelo, P. Cordeiro González, A. Sánchez-Gastaldo, J. Bosch-Barrera, B. Massutí, M. Dómine, C. Camps, A.L. Ortega, M. Provencio
Journal: Journal of Thoracic Oncology (2024)
EP.14A.18 Single-Center Experience of Hyperthermic Intrathoracic Chemoperfusion for Malignant Mesothelioma
Authors: Y. Suzuki, I.S. Sarkaria, O. Okusanya, A. Pennathur, M.J. Schuchert, O. Awais, R. Dhupar, R.M. Levy, J.D. Luketich, N.A. Christie
Journal: Journal of Thoracic Oncology (2024)
EP.04B.05 Discordance Between Nodule and Lung Cancer Location in Early Lung Cancer Detection Cohorts
Authors: O. Ogbeide, W. Liao, M. Ray, J. Goss, A. Patel, T. Qureshi, O. Akinbobola, S. Peppers, A. Harris, A. Porter, K. Dortch, A. Saulsberry, C. Fehnel, M. Smeltzer, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2024)
EP.11C.03 Anlotinib Combined with Immune Checkpoint Inhibitor May Benifit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line
Authors: Y. Lou, R. Li, B. Liu, Y. Li, D. Wang, W. Zhang, B. Han, F. Qian, Y. Zhang, B. Zhang, L. Zhang, W. Ma
Journal: Journal of Thoracic Oncology (2024)
EP.12A.26 Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam
Authors: C.T.M. Pham, M.C. Truong, T.A. Do, P.C. Pham, H.T.T. Nguyen, K.T. Nguyen, T.T.A. Hoang, A.T. Le, H.D.T. Vuong, T.D.N. Nguyen, K.V. Dang, O.T. Nguyen, P.V. Luan, H.M. Nguyen, T.T.H. Vo, K.H. Do, T.H. Vu, H.T.T. Nguyen, T.V. Pham, H.L. Trinh, G.H. Nguyen, P.T.B. Nguyen
Journal: Journal of Thoracic Oncology (2024)
EP.03E.02 Elucidation of Trastuzumab-Deruxtecan Resistance Mechanisms using in Vivo Xenograft Model Reflecting Pharmacokinetics
Authors: S. Yano, Y. Murase, Y. Liu, S. Arai, T. Ueda, N. Terada, H. Koba, Y. Tambo, S. Nanjo
Journal: Journal of Thoracic Oncology (2024)
EP.06G.09 Harnessing Real-World Data for Translational Research in Lung Cancer: MD Anderson Thoracic GEMINI Program
Authors: J.J. Zhang, H. Tran, L. Hong, H. Li, K. Qin, W. Rinsurongkawong, N. Vokes, X. Le, F. Skoulidis, T. Cascone, S. Hubert, J. Wu, J.J. Lee, L. Byers, D. Gibbons, A. Vaporciyan, J. Heymach
Journal: Journal of Thoracic Oncology (2024)
EP.03C.01 The Impact of Systemic Inflammatory Markers on EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Wangsubtawee, N. Trachu, P. Incharoen, N. Jinawath, P. Cheyasawan, N. Monnamo, D. Muntham, P. Sanvarinda, A. Chairoungdua, K. Khiewngam, M. Ngodngamtaweesuk, S. Amponnavarat, N. Reungwetwattana, E. Sirachainan, T.S. Dejthevaporn, P. Chansriwong, T. Reungwetwattana, T. Thamrongjirapat, P. Lumjiaktase
Journal: Journal of Thoracic Oncology (2024)
EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations
Authors: Y-l. Wu, S. Yong, Y. Yao, Z. Cheng-Zhi, L. Wu, J. Zhao, J. Hu, Y. Yin, Y. Lei, X. Gao, M. Tang, R. Gupta, C. Biswas, P. Orfanos
Journal: Journal of Thoracic Oncology (2024)
EP.08F.08 Safety and Efficacy of Durvalumab Consolidation Therapy after Chemoradiotherapy in NSCLC Patients Positive for Antinuclear Antibodies
Authors: A. Tsukaguchi, A. Tamiya, S. Fukuda, Y. Iwahashi, K. Kanaoka, Y. Tanaka, Y. Inagaki, Y. Taniguchi, K. Nakao, T. Kagawa, Y. Matsuda, K. Okishio
Journal: Journal of Thoracic Oncology (2024)
EP.15B.02 Real-World Data from Advanced Practice Nurse Care in Lung Cancer in a Private Clinic in Brazil
Authors: G. Farias, I. Borchardt, G. Moreira, V. Figueiredo, N. Afonso, G. Veloso, M. Reis, B. Silva, C. Santos, P. Marchi, F. Taveira, C. Gil, T. Montella
Journal: Journal of Thoracic Oncology (2024)
EP.17F.03 An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway
Authors: M. Majem, I.G. Sullivan, A. Torrego, J. Surrallés, J. Purdy, M. Ascorbe Carmona, H. Dunsford, M. Wubs
Journal: Journal of Thoracic Oncology (2024)
EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC
Authors: N. Vokes, L. Paz-Ares, F. Cappuzzo, N. Yamamoto, J.E. Gray, T. Owonikoko, R. Ariyasu, H. Ishii, J.H. Kang, S.-H. Lee, R. Hallwachs, A. Coenen-Stass, B. Sarholz, L. Pudelko, J. Kaur Mukker, C. Moulin, I. Gounaris, L.C. Villaruz
Journal: Journal of Thoracic Oncology (2024)
P4.17F.04 Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System - The Hong Kong Experience
Authors: K.M. Cheung, C.H.L. Wong, J.K.S. Fong, V.H.F. Lee, M.Y. Lim, T.Y. Kam, S.F. Nyaw, C.K. Kwan, F.S.T. Mok, A.W.M. Lee, H.H.Y. Yiu
Journal: Journal of Thoracic Oncology (2024)
Correction: Conservative or liberal oxygen targets in patients on venoarterial extracorporeal membrane oxygenation
Authors: Aidan Burrell, Michael J Bailey, Rinaldo Bellomo, Hergen Buscher, Glenn Eastwood, Paul Forrest, John F Fraser, Bentley Fulcher, David Gattas, Alisa M Higgins, Carol L Hodgson, Edward Litton, Emma-Leah Martin, Priya Nair, Sze J Ng, Neil Orford, Kelly Ottosen, Eldho Paul, Vincent Pellegrino, Liadain Reid, Kiran Shekar, Richard J Totaro, Tony Trapani, Andrew Udy, Marc Ziegenfuss, David Pilcher
Journal: Intensive Care Medicine (2024)
Maternal Glycemic Status and Longitudinal Fetal Body Composition and Organ Volumes Based on Three-Dimensional Ultrasonography
Authors: Kathryn A. Wagner, Jessica L. Gleason, Zhen Chen, Cuilin Zhang, Stefanie N. Hinkle, Dian He, Wesley Lee, Roger B. Newman, John Owen, Daniel W. Skupski, William A. Grobman, Seth Sherman, Fasil Tekola-Ayele, Jagteshwar Grewal, Katherine L. Grantz
Journal: Diabetes Care (2024)

OBJECTIVE Gestational diabetes mellitus (GDM) increases the risk of fetal overgrowth as measured by two-dimensional ultrasonography. Whether fetal three-dimensional (3D) soft tissue and organ volumes provide additional insight into fetal overgrowth is unknown. RESEARCH DESIGN AND METHODS We prospectively evaluated longitudinal 3D fetal body composition and organ volumes in a diverse U.S. singleton pregnancy cohort (2015–2019). Women were diagnosed with GDM, impaired glucose tolerance (IGT), or normal glucose tolerance (NGT). Up to five 3D ultrasound scans measured fetal body composition and organ volumes; trajectories were modeled using linear mixed models. Overall and weekly mean differences in fetal 3D trajectories were tested across glycemic status, adjusted for covariates. RESULTS In this sample (n = 2,427), 5.2% of women had GDM, and 3.0% had IGT. Fetuses of women who developed GDM compared with NGT had larger fractional arm and fractional fat arm volumes from 26 to 35 weeks, smaller fractional lean arm volume from 17 to 22 weeks, and larger abdominal area from 24 to 40 weeks. Fetuses of women with IGT had similar growth patterns, which manifested later in gestation and with larger magnitudes, and had larger fractional lean arm volume. No overall differences were observed among thigh or organ volumes across glycemic status. CONCLUSIONS Body composition differed in fetuses of GDM-complicated pregnancies, including larger arm and abdominal measures across the second and third trimesters. Patterns were similar in IGT-complicated pregnancies except that they occurred later in gestation and with larger magnitudes. Future research should explore how lifestyle and medication may alter fetal fat accumulation trajectories among hyperglycemic pregnancies.
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
Authors: Jonathan Weitz, Daisuke Nishizaki, Joy Liau, Jay Patel, Isabella Ng, Siming Sun, Dana Ramms, Jingjing Zou, Brian Wishart, Jordan Rull, Joel Baumgartner, Kaitlyn Kelly, Rebekah White, Jula Veerapong, Mojgan Hosseini, Hitendra Patel, Gregory Botta, J. Sylvio Gutkind, Herve Tiriac, Shumei Kato, Andrew M. Lowy
Journal: Journal of Clinical Oncology (2024)

PURPOSE Mucinous neoplasms of the gastrointestinal tract are characterized by a propensity for metastasis to the peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC). A subset of these tumors, most often originating in the appendix, harbor mutations in the GNAS oncogene. While the natural history of GNAS -mutant PMC varies, patient outcomes are generally poor, as is response to cytotoxic chemotherapy. The purpose of this study was to evaluate the clinical efficacy of single-agent palbociclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, in patients with GNAS -mutant PMC. PATIENTS AND METHODS We enrolled 16 patients with PMC in a single-arm personalized cancer therapy trial. For all patients, tumor tissue and/or circulating tumor DNA genomic profiling using next-generation sequencing and, when possible, PD-L1 expression, tumor mutational burden, and microsatellite instability status was assessed. Twelve of 16 patients had previous disease progression on at least one previous line of chemotherapy. The primary tumor was appendix in 13 patients, unknown in two patients, and pancreas in one patient. Eleven cases were classified as low grade, and five as high grade. RESULTS In 13 of 16 patients, we observed a decrease in carcinoembryonic antigen (CEA), and in six patients, the CEA declined by &gt;50%. As measured by clinical and modified peritoneal RECIST criteria, 50% of evaluable patients had stable disease after 12 months of palbociclib. At a median follow-up of 17.6 months, median survival has not been reached. Clinical response to CDK4/6 inhibition was mirrored in tumors with GNAS mutation and mucinous histology using an ex vivo preclinical platform. CONCLUSION CDK4/6 inhibition with palbociclib had clinical activity in PMC characterized by mutations in GNAS that was superior to that previously reported with cytotoxic chemotherapy. CDK4/6 inhibition is a novel therapeutic strategy worthy of further evaluation in this subgroup of gastrointestinal neoplasms.
Exploring complexities of Alzheimer’s disease: New insights into molecular and cellular mechanisms of neurodegeneration and targeted therapeutic interventions
Authors: Abdulmajeed G Almutary, M Yasmin Begum, Ashish Kumar Kyada, Saurabh Gupta, S Renuka Jyothi, Kamlesh Chaudhary, Swati Sharma, Aashna Sinha, Mosleh Mohammad Abomughaid, Mohd Imran, Sorabh Lakhanpal, Ahmad O Babalghith, Eman Adnan Abu-Seer, D Avinash, Hassan A Alzahrani, Abdulghani A Alhindi, Danish Iqbal, Sandeep Kumar, Niraj Kumar Jha, Saad Alghamdi
Journal: Ageing Research Reviews (2024)
Poly(β-amino ester) polymer library with monomer variation for mRNA delivery
Authors: Hong Lyun Kim, Gurusamy Saravanakumar, Seowon Lee, Subin Jang, Seonwoo Kang, Mihyeon Park, Sivasangu Sobha, So-Hee Park, Soo-Min Kim, Jung-Ah Lee, Eunkyung Shin, You-Jin Kim, Hye-Sook Jeong, Dokeun Kim, Won Jong Kim
Journal: Biomaterials (2024)
P2.17A.09 Real-World Study of the Efficacy and Safety Analysis of Immunotherapy in Advanced Lung Cancer Under Internet-Based Full-course Management
Authors: D. Zheng, Y. Shang, J. Ni, Y. Guo, Z. Dai, W. Heng, Y. Yizhuo, W. Wang, Y. Du, X. LI, X. Tan, C. Liu, Q. Zhan, J. Yan, J. Wang, J. Zhang, B. Xie, x. zhao, F. PAN, L. Jiang
Journal: Journal of Thoracic Oncology (2024)
Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li’s Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027
Authors: Amanda A Myers, Ashish M Kamat
Journal: European Urology (2024)
Re: Frédéric Panthier, Vineet Gauhar, Eugenio Ventimiglia, Jia-Lun Kwok, Etienne Xavier, Olivier Traxer. Rethinking Stone-free Rates and Surgical Outcomes in Endourology: A Point of View from PEARLS Members. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.06.001
Authors: Roger L Sur
Journal: European Urology (2024)
TopoTxR: A topology-guided deep convolutional network for breast parenchyma learning on DCE-MRIs
Authors: Fan Wang, Zhilin Zou, Nicole Sakla, Luke Partyka, Nil Rawal, Gagandeep Singh, Wei Zhao, Haibin Ling, Chuan Huang, Prateek Prasanna, Chao Chen
Journal: Medical Image Analysis (2024)
Anti-Pyroptosis Biomimetic Nanoplatform loading Puerarin for Myocardial Infarction Repair: From Drug Discovery to Drug Delivery
Authors: Kun Wang, Yu Sun, Ke Zhu, Yiqiong Liu, Xiao Zheng, Zichen Yang, Fulong Man, Li Huang, Ziyang Zhu, Qi Huang, Yan Li, Haiqing Dong, Jun Zhao, Yongyong Li
Journal: Biomaterials (2024)
Stress CMR Perfusion Imaging in the Medicare-Eligible Population
Authors: Yin Ge, Panagiotis Antiochos, Benedikt Bernhard, Bobak Heydari, Kevin Steel, Scott Bingham, J Ronald Mikolich, Andrew E Arai, W Patricia Bandettini, Amit R Patel, Sujata M Shanbhag, Afshin Farzaneh-Far, John F Heitner, Chetan Shenoy, Steve W Leung, Jorge A Gonzalez, Dipan J Shah, Subha V Raman, Victor A Ferrari, Jeanette Schulz-Menger, Matthias Stuber, Orlando P Simonetti, Raymond Y Kwong
Journal: JACC. Cardiovascular imaging (2024)
Human assembloids reveal the consequences of CACNA1G gene variants in the thalamocortical pathway
Authors: Ji-Il Kim, Yuki Miura, Min-Yin Li, Omer Revah, Sridhar Selvaraj, Fikri Birey, Xiangling Meng, Mayuri Vijay Thete, Sergey D Pavlov, Jimena Andersen, Anca M Pașca, Matthew H Porteus, John R Huguenard, Sergiu P Pașca
Journal: Neuron (2024)